NCT03188978View on ClinicalTrials.gov

High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Primary Arteriovenous Fistula Failure
Interventions
DRUG

Atorvastatin 40mg

one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.

OTHER

Placebo

one tablet daily for 8 weeks starting 2 weeks before the AVF creation.

Trial Locations (1)

12208

Albany Medical College, Albany

Sponsors
All Listed Sponsors
lead

Albany Medical College

OTHER

NCT03188978 - High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study | Biotech Hunter | Biotech Hunter